捆绑白丝jk震动捧娇喘视频_国产一级不卡黄色av_久爱视频2019午夜视频_2020国产特级黄色自拍_亚洲熟妇AV日韩熟妇AV_国产精品欧美天美传媒_水蜜桃亚洲成人无码_歐美在線視頻網_日韩在线成人毛片_人妻激情中文字幕

 

 

 

As of now, several listed pharmaceutical companies have disclosed their performance forecasts for the third quarter. Based on the disclosed information, some companies are expected to see an increase in performance. Among them, Garden Biology is expected to achieve a year-on-year increase of 183.68% to 278.25% in net profit attributable to shareholders of the listed company in the third quarter, ranging from 90 million yuan to 120 million yuan.

 

 

 

According to the semi annual report of Garden Biology, the company achieved a net profit of 142 million yuan in the first half of the year, while the net profit in the second quarter was only 50.6309 million yuan. Based on this calculation, the company's net profit in the third quarter increased by 77.76% to 137% month on month.

 

 

 

Regarding profit growth, Garden Biology stated that during the reporting period, the operating revenue and gross profit of the vitamin sector increased year-on-year. In addition, the confirmed share based payment expenses for the company's employee stock ownership plan have decreased year-on-year. The impact of non recurring gains and losses on net profit is expected to be approximately 40 million yuan.

 

 

 

The net profit attributable to the parent company for the third quarter of 2024 is expected to be at least 28.2841 million yuan, and up to 39.4111 million yuan, far exceeding the total of the previous two quarters. According to the 2024 interim report of Shengnuo Biotechnology, the company's main operating revenue for the first half of the year was 199 million yuan; The net profit attributable to the parent company was 21.7876 million yuan.

 

 

 

It is reported that the sales of Shengnuo Biological Peptide products grew rapidly in the third quarter. In mid to late September of this year, Shengnuo Biotechnology disclosed to the public that its wholly-owned subsidiary, Shengnuo Pharmaceutical, had signed a "Product Procurement Contract" with a customer to supply GLP-1 peptide raw materials, with a maximum contract amount of 350 million yuan.

 

 

 

Zuo Li Pharmaceutical is expected to achieve a net profit attributable to shareholders of the listed company of 115 million to 130 million yuan in the third quarter, a year-on-year increase of 28.92% to 45.73%. Regarding the reasons for performance changes, the company stated that during the reporting period, it continued to strengthen market expansion based on the advantages of its three core products, Wuling Capsules, Lingze Tablets, and Bailing Tablets, which are listed in the National Essential Medicines List. Among them, the sales revenue of Wuling Capsules and Lingze Tablets continued to grow well in the market; With the increase of registered varieties, the sales revenue of traditional Chinese medicine formula granules has significantly increased compared to the same period last year.

 

 

 

Analysts believe that in the first half of 2024, the overall operating revenue and non attributable net profit of listed companies in the pharmaceutical industry will decrease by 1.10% and 6.57% year-on-year, respectively. The business trend in the second quarter is close to that in the first quarter, which is mainly affected by the base effect of some companies, policy disturbance, external environment and other factors. The base effect mainly includes traditional Chinese patent medicines and simple preparations companies, vaccines, IVD, CXO companies, etc. in the cold breathing category. The industry's resilience is still evident, with outstanding performance from leading companies. Looking ahead to the second half of 2024, it is expected that the overall growth rate of the pharmaceutical industry will continue to rebound.

 

 

 

Looking ahead to the third quarter performance, some analysts believe that the pharmaceutical sector and the company are diverging. In terms of pharmaceuticals and industrial chain, the pharmaceutical sector continues to innovate and transform, and its performance is gradually climbing; CXO overseas demand resumes, waiting for domestic demand to recover; The upstream short-term profit side of the pharmaceutical industry chain is under significant pressure, and the long-term high growth logic of the industry remains unchanged.